BIOSPAIN 2026

Cell and gene therapies (CGT) have revolutionised the treatment of many conditions and they continue to attract significant levels of investment. Their development faces unique challenges, ranging from technical complexity, regulation, scaling production, and the requirement of innovative commercialization models. This roundtable will explore how CGT can be effectively translated into innovation that reaches the market, creates value, and improves people’s lives. A range of topics will be covered, with particular emphasis on some key challenges such as response durability, toxicity management, targeting of solid tumours, and the development of robust analytical workflows for functional characterisation, including approaches such as real-time cytotoxicity assays and multimodal cell profiling.